ZAIVALIFESCIENCES
Brivcept 50 pharmaceutical pack by Zaiva Lifesciences

CNS & Neuropsychiatry

Brivcept 50

Brivaracetam · 50 mg

An antiseizure medicine with high-affinity SV2A binding, used in focal-onset seizure management.

BrandBrivcept 50
CompositionBrivaracetam
Strength50 mg
Dosage formTablet

Overview

Antiseizure therapy in focal-onset epilepsy according to the approved local indication.

  • Brivaracetam has high affinity for synaptic vesicle protein SV2A.
  • The therapeutic objective is seizure control; response and tolerability are individual.
  • Choice of antiseizure therapy depends on seizure type, comorbidity, interactions and reproductive considerations.

Composition & dosage

Composition: Brivaracetam · 50 mg

Dosage form: Tablet

Dosage: As prescribed by the doctor.

How it works

High-affinity binding to synaptic vesicle protein 2A (SV2A); the exact anticonvulsant mechanism is not fully established.

  1. High-affinity binding to synaptic vesicle protein 2A (SV2A)
  2. the exact anticonvulsant mechanism is not fully established.

Phase III randomized trials and meta-analytic evidence support adjunctive brivaracetam for focal-onset seizures, with responder and seizure-frequency benefits versus placebo.

Safety information

  • Somnolence, dizziness and fatigue may occur.
  • Monitor for behavioural or psychiatric symptoms and suicidality as with antiseizure medicines.
  • Do not change or stop antiseizure therapy abruptly without clinical supervision.

Review the current approved prescribing information, contraindications, interactions, organ-function considerations, pregnancy/lactation advice and patient-specific risks before prescribing.

Evidence context

Phase III randomized trials and meta-analytic evidence support adjunctive brivaracetam for focal-onset seizures, with responder and seizure-frequency benefits versus placebo.

Efficacy varies by patient and background therapy; the evidence is for brivaracetam, not specifically for the Zaiva brand.